Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 4/2013

Inhalt (20 Artikel)

Original Paper

Exocyst complex component Sec8: a presumed component in the progression of human oral squamous-cell carcinoma by secretion of matrix metalloproteinases

Ayumi Yamamoto, Atsushi Kasamatsu, Shunsaku Ishige, Kazuyuki Koike, Kengo Saito, Yukinao Kouzu, Hirofumi Koike, Yosuke Sakamoto, Katsunori Ogawara, Masashi Shiiba, Hideki Tanzawa, Katsuhiro Uzawa

Original Paper

Diagnostic and predictive role of cell-free midkine in malignant pleural effusions

Mingming Lv, Yongbin Mou, Ping Wang, Yueqiu Chen, Tingting Wang, Yayi Hou

Original Paper

CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary

C. Bachmann, E. M. Grischke, T. Fehm, A. Staebler, J. Schittenhelm, D. Wallwiener

Original Paper

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

Zhihong Ma, Hongwei Li, Bin Wang, Qibin Shen, Enhai Cui, Lishan Min, Fuchu Qian, Jinliang Ping, Licheng Dai

Original Paper

Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal 18F-FDG PET and gene expression analysis

Maren Bretschi, Caixia Cheng, Hendrik Witt, Antonia Dimitrakopoulou-Strauss, Ludwig G. Strauss, Wolfhard Semmler, Tobias Bäuerle

Original Paper

ALY as a potential contributor to metastasis in human oral squamous cell carcinoma

Yasuhiro Saito, Atsushi Kasamatsu, Ayumi Yamamoto, Toshihiro Shimizu, Hidetaka Yokoe, Yosuke Sakamoto, Katsunori Ogawara, Masashi Shiiba, Hideki Tanzawa, Katsuhiro Uzawa

Original Paper

Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy

Kohei Shitara, Satoshi Yuki, Kentaro Yamazaki, Yoichi Naito, Hiraku Fukushima, Yoshito Komatsu, Hirofumi Yasui, Toshimi Takano, Kei Muro

Original Paper

The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells

Ulf Schnetzke, Mike Fischer, Anne-Kathrin Kuhn, Bärbel Spies-Weisshart, Elisabeth Zirm, Andreas Hochhaus, Jörg P. Müller, Sebastian Scholl

Original Paper

Invasive breast cancer: a significant correlation between histological types and molecular subgroups

A. Caldarella, C. Buzzoni, E. Crocetti, S. Bianchi, V. Vezzosi, P. Apicella, M. Biancalani, A. Giannini, C. Urso, F. Zolfanelli, E. Paci

Original Paper

Expression of vascular endothelial growth factor and transcription factors HIF-1, NF-kB expression in squamous cell carcinoma of head and neck; association with proteasome and calpain activities

Liudmila V. Spirina, Irina V. Kondakova, Evgeny L. Choynzonov, Svetlana Y. Chigevskaya, Dmitry A. Shishkin, Denis Y. Kulbakin

Original Paper

Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization

Eun Sun Jang, Jung-Hwan Yoon, Jin Wook Chung, Eun Ju Cho, Su Jong Yu, Jeong-Hoon Lee, Yoon Jun Kim, Hyo-Suk Lee, Chung Yong Kim

Original Paper

Predictors of early distant metastasis in women with breast cancer

Erick Sta. Rosa Mendoza, Emmanuel Moreno, Priscilla Baetiong Caguioa

Original Paper

Overexpression of LAPTM4B: an independent prognostic marker in breast cancer

Min Xiao, Shusheng Jia, Hongbin Wang, Jinsong Wang, Yuanxi Huang, Zhigao Li

Original Paper

Enhanced production of CTGF and IL-11 from highly metastatic hepatoma cells under hypoxic conditions: an implication of hepatocellular carcinoma metastasis to bone

Ya-Bo Gao, Zuo-Lin Xiang, Le-Yuan Zhou, Zhi-Feng Wu, Jia Fan, Hai-Ying Zeng, Zhao-Chong Zeng

Original Paper

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy

Michael Haas, Volker Heinemann, Frank Kullmann, Rüdiger P. Laubender, Christina Klose, Christiane J. Bruns, Stefan Holdenrieder, Dominik P. Modest, Christoph Schulz, Stefan Boeck

Original Paper

Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patients

Berrin Tunca, Gulcin Tezcan, Gulsah Cecener, Unal Egeli, Abdullah Zorluoglu, Tuncay Yilmazlar, Secil Ak, Omer Yerci, Ersin Ozturk, Gorkem Umut, Turkkan Evrensel

Original Paper

A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery

Juan Pu, Shan-shan Qin, Jin-xia Ding, Yan Zhang, Wei-guo Zhu, Chang-hua Yu, Tao Li, Guang-zhou Tao, Fu-zhi Ji, Xi-lei Zhou, Ji-hua Han, Ya-lin Ji, Jun-xia Sun

Original Paper

Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression

Eun Shin, Do Joong Park, Hyung-Ho Kim, Nam Hee Won, Gheeyoung Choe, Hye Seung Lee

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.